| Want to jump right to here next time? Bookmark: www.canpku.org/education/treatments/ucd |
UCD Treatments and Therapies in Canada
Urea Cycle Disorders (UCDs) are managed through individualized treatment plans guided by a metabolic clinic. Management focuses on preventing the buildup of ammonia, supporting safe protein intake, and responding quickly to metabolic instability. Treatment varies depending on the specific subtype and clinical presentation.
Important: Treatment decisions depend on subtype, age, biochemical stability, laboratory monitoring, clinical history, and emergency preparedness. Always follow your clinic’s recommendations.
Core treatment approaches
For many individuals with UCDs, treatment includes dietary management, medical formula when indicated, medications to help remove ammonia (sometimes called “nitrogen scavengers”), and ongoing biochemical monitoring.
Dietary management and medical nutrition
Many individuals with UCDs follow a carefully controlled protein intake to reduce ammonia production. Some may require specialized metabolic formulas or essential amino acid supplements to ensure adequate nutrition while limiting ammonia risk. Dietary targets vary by subtype and by individual tolerance.
Related education: Nourish | Low Protein Meal Planning Tools
Ammonia-lowering medications (nitrogen scavengers)
Some individuals with UCDs are prescribed medications that help the body remove excess nitrogen through alternative pathways. Your clinic will decide what is appropriate based on subtype, age, lab monitoring, and your clinical history.
Chronic (ongoing) ammonia-scavenging medications (oral):
- RAVICTI® (glycerol phenylbutyrate) – an oral nitrogen-binding medication used for the chronic management of certain UCDs. (Coverage and access can vary by province/plan.)
- PHEBURANE® (sodium phenylbutyrate) – an oral nitrogen-binding medication used for the chronic management of certain UCDs.
Acute (emergency) ammonia-scavenging medications (hospital):
- AMMONUL® (sodium phenylacetate + sodium benzoate, IV) – a nitrogen-binding medication used in hospital settings as part of emergency management for acute hyperammonemia in UCDs (timing and protocols are clinic/hospital-directed).
Amino acid supplements used in some UCD subtypes:
- Citrulline (supplement/medical product; brand varies)
- Arginine (supplement/medical product; brand varies)
Note: Families sometimes hear about UCD products used in other countries. For example, OLPRUVA (sodium phenylbutyrate) is a U.S. product. Whether a medication is authorized and marketed in Canada can varies – your clinic can help confirm current Canadian access and coverage for your situation.
Emergency management and hyperammonemia
Individuals with UCDs may be at risk of hyperammonemic episodes, particularly during illness, fasting, surgery, or physiological stress. Rapid increases in ammonia can lead to neurological symptoms and require urgent hospital care.
Emergency letters, sick-day protocols, and clear hospital communication plans are essential parts of care. Families and adult patients should ensure emergency documentation is accessible at all times.
Tip: Ask your clinic if you have an emergency letter and if it needs updating.
Ongoing monitoring and long-term care
Regular monitoring of ammonia and related laboratory markers helps clinics assess metabolic stability and adjust treatment plans. Growth, development, nutritional status, and neurological health are monitored across life stages.
Transition to adult care and pregnancy planning require specialized metabolic supervision.
Liver transplantation
In some cases, liver transplantation may be considered. Transplant can significantly reduce the risk of recurrent hyperammonemia in certain subtypes, but it is not considered a cure and requires lifelong medical follow-up.
Transplant decisions are complex and individualized. Please refer to your clinic for what might be best for you. For research literature and case discussions, visit the UCD Studies page.
Research, trials, and registries
Looking for research studies, registries, or clinical trials (including studies that may be recruiting)? We track research and studies on our dedicated page:
UCD Studies & Trials UCD Registry
Optional external resources:
You can also explore reputable external trial listings and clinician resources:
Sources and references
- Health Canada – Drug Product Database (DPD): how to verify what is authorized in Canada
- Health Canada – Summary Basis of Decision: RAVICTI (glycerol phenylbutyrate)
- Health Canada – Product Monograph: RAVICTI (glycerol phenylbutyrate)
- Health Canada – Summary Basis of Decision: PHEBURANE (sodium phenylbutyrate)
- Health Canada – Product Monograph: PHEBURANE (sodium phenylbutyrate)
- Urea Cycle Disorders Consortium (UCDC) – Treatment Guidelines
- DailyMed (US) – Sodium phenylacetate + sodium benzoate injection (AMMONUL class)
- FDA (US) – OLPRUVA (sodium phenylbutyrate) label
External links are shared for education and support. CanPKU+ does not control external content. Always confirm medical guidance with your metabolic clinic.
